How many drugs treat Renal transplant rejection?

Drug Landscape tracks 10 marketed treatments for Renal transplant rejection (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/renal-transplant-rejection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Renal transplant rejection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renal transplant rejection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Renal transplant rejection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ides	IMLIFIDASE	Hansa Biopharma AB		Immunoglobulin gamma (IgG), heavy chain	2020-01-01
Nulojix	BELATACEPT	Bristol-Myers Squibb	Selective T Cell Costimulation Blocker [EPC]	T-lymphocyte activation antigen CD80	2011-01-01
Chrft5	BASILIXIMAB	Novartis	Interleukin-2 Receptor Blocking Antibody [EPC]	Interleukin-2 receptor subunit alpha	1998-01-01
Zenapax	DACLIZUMAB	Hoffman-La Roche	Interleukin-2 Receptor Blocking Antibody	Interleukin-2 receptor	1997-01-01
Prograf	TACROLIMUS	Astellas Pharma	Calcineurin Inhibitor Immunosuppressant	Interferon gamma	1994-01-01
Orthoclone Okt3	MUROMONAB-CD3	Ortho Biotech	CD3 Blocker Immunosuppressant	T-cell surface glycoprotein CD3	1992-01-01
Simulect	Simulect	Astellas Pharma Inc		Interleukin-2 receptor subunit alpha
Nulojix	Nulojix	Bristol-Myers Squibb		T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86
Zenapax	Zenapax	National Institute of Neurological Disorders and Stroke (NINDS)		Interleukin-2 receptor
Muromonab	Muromonab	St. Jude Children's Research Hospital		T-cell surface glycoprotein CD3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 2 drugs in Renal transplant rejection
Astellas Pharma Inc · 1 drug in Renal transplant rejection
Hansa Biopharma AB · 1 drug in Renal transplant rejection
Hoffman-La Roche · 1 drug in Renal transplant rejection
National Institute of Neurological Disorders and Stroke (NINDS) · 1 drug in Renal transplant rejection
Novartis · 1 drug in Renal transplant rejection
Ortho Biotech · 1 drug in Renal transplant rejection
Astellas Pharma · 1 drug in Renal transplant rejection
St. Jude Children's Research Hospital · 1 drug in Renal transplant rejection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Renal transplant rejection:

Cite this brief

Drug Landscape (2026). Renal transplant rejection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-transplant-rejection. Accessed 2026-06-09.

Renal transplant rejection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing